Concepedia

Pablo Castañeda

PC

Statistics

Publications

8

Citations

318

H-Index

8

Active since

2011

Affiliations

GlaxoSmithKline (Spain)(Current)

GlaxoSmithKline (United Kingdom)

Medicines for Malaria Venture

GlaxoSmithKline (France)

GlaxoSmithKline (United States)

Pablo Castañeda is an author at GlaxoSmithKline (Spain) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

2011–2023

8

Publications

8

Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of <i>Mycobacterium tuberculosis</i> InhA

Lourdes Encinas, Heather P. O’Keefe, Margarete Neu et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

, , +17

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor

María Martínez-Hoyos, Esther Pérez‐Herrán, Gülçin Gülten et al. · EBioMedicine · 2016 · 81 citations · Full text

, , +16

Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen

Laura M. Sanz, María-Belén Jiménez-Díaz, Benigno Crespo et al. · Antimicrobial Agents and Chemotherapy · 2011 · 28 citations · Full text

, , +16

Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials

Matthew McConville, Jorge Mozo-Fernández, Íñigo Angulo‐Barturen et al. · Journal of Medicinal Chemistry · 2015 · 24 citations · Full text

, , +17

Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors

Michael G. Thomas, Kate McGonagle, Paul Rowland et al. · Journal of Medicinal Chemistry · 2023 · 23 citations · Full text

, , +16

1–5 of 8